O
LLY icon

OrbiMed’s Eli Lilly LLY Stock Holding History

OrbiMed’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$218M Sell
236,800
-64,400
-21% -$65.3M 4.32% 4
2025
Q4 		$324M Hold
301,200
– – 6.61% 2
2025
Q3 		$230M Sell
301,200
-36,400
-11% -$27.1M 5.4% 3
2025
Q2 		$263M Hold
337,600
– – 6.57% 3
2025
Q1 		$279M Hold
337,600
– – 6.65% 4
2024
Q4 		$261M Hold
337,600
– – 5.36% 4
2024
Q3 		$299M Hold
337,600
– – 5.43% 3
2024
Q2 		$306M Sell
337,600
-23,200
-6% -$18.6M 6.04% 2
2024
Q1 		$281M Sell
360,800
-4,600
-1% -$3.27M 5.14% 2
2023
Q4 		$213M Buy
365,400
+179,400
+96% +$105M 4.25% 3
2023
Q3 		$99.9M Hold
186,000
– – 2.12% 10
2023
Q2 		$87.2M Hold
186,000
– – 1.58% 20
2023
Q1 		$63.9M Buy
+186,000
New +$62.7M 1.25% 23
2018
Q1 		– Sell
-2,288,000
Closed -$193M – 146
2017
Q4 		$193M Sell
2,288,000
-787,000
-26% -$67M 2.44% 12
2017
Q3 		$263M Hold
3,075,000
– – 2.51% 8
2017
Q2 		$253M Sell
3,075,000
-255,200
-8% -$20.8M 2.65% 7
2017
Q1 		$280M Buy
3,330,200
+591,200
+22% +$47.4M 3.18% 6
2016
Q4 		$201M Buy
2,739,000
+698,500
+34% +$52M 2.57% 9
2016
Q3 		$164M Buy
2,040,500
+563,700
+38% +$45.1M 1.87% 15
2016
Q2 		$116M Sell
1,476,800
-1,064,500
-42% -$80.1M 1.21% 29
2016
Q1 		$183M Buy
2,541,300
+928,300
+58% +$70.2M 1.93% 15
2015
Q4 		$136M Buy
1,613,000
+341,000
+27% +$28.3M 1.23% 27
2015
Q3 		$106M Buy
+1,272,000
New +$107M 1.07% 33
2014
Q4 		– Sell
-112,000
Closed -$7.26M – 135
2014
Q3 		$7.26M Sell
112,000
-288,000
-72% -$18.2M 0.08% 106
2014
Q2 		$24.9M Sell
400,000
-143,000
-26% -$8.53M 0.29% 59
2014
Q1 		$32M Buy
+543,000
New +$30.3M 0.39% 49

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OrbiMed's LLY Position: Q1 2026 in Review

OrbiMed reduced its Eli Lilly (LLY) stake by 21% in Q1 2026, selling an estimated $65.3M and leaving 236,800 shares worth $218M. The position accounts for 4.32% of the portfolio, ranked #4.

OrbiMed first reported a position in LLY in Q1 2014 and has held it in 26 quarters since. The position peaked at $324M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • OrbiMed held 236,800 shares of Eli Lilly worth $218M as of Q1 2026.
  • OrbiMed sold 64,400 Eli Lilly shares in Q1 2026, an estimated $65.3M.
  • Eli Lilly made up 4.32% of OrbiMed's portfolio in Q1 2026, its #4 holding.
  • OrbiMed first reported a position in Eli Lilly in Q1 2014 and has held it in 26 quarters since.
  • OrbiMed's Eli Lilly position peaked at $324M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.